Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Earnings data Q1 2024

SNDX reports progress in pivotal trials and leadership transitions

SNDX showcased progress in pivotal trials, financial stability, and leadership transitions. The company faces challenges in addressing specific patient responses and resistance mechanisms. However, opportunities lie in expanding drug candidates and pursuing business development for targeted oncology assets.

Syndax Pharmaceuticals reports positive trial data and strong cash position

Syndax Pharmaceuticals showcased positive pivotal trial data, a strong cash position, and plans for pipeline expansion. However, challenges in assessing therapy benefits and regulatory approval requirements exist. Significant opportunities lie in upcoming data releases, potential filings, and commercialization options for axatilimab.

Syndax Pharmaceuticals reports positive pivotal data and strong financial position

Syndax Pharmaceuticals showcased strong performance with positive pivotal data, maintained a robust financial position, and addressed physician confidence in using revumenib. While facing enrollment challenges, the company is focused on upcoming value-generating milestones and opportunities for expansion.

Syndax Pharmaceuticals excels in 2023, poised for growth in 2024

Syndax Pharmaceuticals had a successful year in 2023, advancing key products towards regulatory approval and strengthening its financial position. The company is poised for growth in 2024, with a focus on commercialization and achieving ambitious milestones.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) rose in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 3.57% year over year to ($0.54), which beat the estimate of ($0.65).

Recap: Syndax Pharmaceuticals Q1 Earnings

WALTHAM, Mass., May 11, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the first quarter ended March 31, 2021.

Syndax Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Clinical and Business Update

WALTHAM, Mass., May 4, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, announced today that it will release its first quarter 2021 financial results on Tuesday, May 11, after the close of the U.S. financial markets.

Syndax to Announce First Quarter 2021 Financial Results and Host Conference Call and Webcast on May 11, 2021

Syndax (SNDX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Syndax (SNDX) Moves 10.7% Higher: Will This Strength Last?

The company announced results from an early-stage clinical study.

Why Syndax Pharmaceuticals Stock Is Sinking Today

KalVista Pharma

CRISPR Therapeutics

CRISPR Therapeutics AG (NASDAQ: CRSP), Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX) and KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) were among the early movers in the biopharma space Tuesday. CRISPR Rises On Gene Editing Therapy Pact With Vertex: CRISPR announced an amended collaboration agreement with Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) with respect to CTX001, an investigational CRISPR/Cas9-based gene editing therapy that is being developed as a potentially curative therapy for sickle cell disease and transfusion-dependent beta-thalassemia.

Why Crispr, KalVista And Syndax Are Moving Today

WALTHAM, Mass., April 20, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated positive data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with mixed lineage leukemia rearranged (MLLr) and nucleophosmin (NPM1c) mutant relapsed/refractory (R/R) acute leukemias.

Syndax Announces Positive Interim Data Demonstrating Robust Clinical Activity in Phase 1 Portion of the AUGMENT-101 Trial of SNDX-5613 in Patients with Genetically-Defined Acute Leukemias

WALTHAM, Mass., April 15, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and live webcast to provide updated data from the Phase 1 dose escalation portion of the ongoing Phase 1/2 AUGMENT-101 trial of SNDX-5613 in patients with relapsed or refractory acute leukemias on Tuesday, April 20, 2021 at 8:00 a.m.

Syndax Pharmaceuticals to Host Conference Call and Webcast to Provide Updated Data from Phase 1 Portion of AUGMENT-101 Trial of SNDX-5613 in Patients with Acute Leukemias

The FDA grants orphan drug designation to Syndax's (SNDX) axatilimab for the treatment of patients with idiopathic pulmonary fibrosis. Shares up.

Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for IPF

WALTHAM, Mass., April 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab, its anti-CSF-1R monoclonal antibody, for the treatment of patients with idiopathic pulmonary fibrosis (IPF).

Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Idiopathic Pulmonary Fibrosis

The FDA bestows an orphan drug designation on Syndax's (SNDX) axatilimab for the treatment of patients with chronic graft versus host disease. Shares up.

Syndax's (SNDX) Axatilimab Gets FDA's Orphan Drug Tag for GVHD

WALTHAM, Mass., March 31, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to axatilimab, its anti-CSF-1R monoclonal antibody, for the treatment of patients with chronic graft versus host disease (cGVHD).

Syndax Announces Orphan Drug Designation Granted to Axatilimab for Treatment of Chronic Graft Versus Host Disease

Syndax Pharmaceuticals, Inc. (SNDX) CEO Dr. Briggs Morrison on Q4 2020 Results - Earnings Call Transcript

Shares of Syndax Pharmaceuticals (NASDAQ:SNDX) were flat in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share increased 0.00% year over year to ($0.44), which beat the estimate of ($0.49).

Syndax Pharmaceuticals: Q4 Earnings Insights

WALTHAM, Mass., March 8, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today reported its financial results for the fourth quarter ended...

Syndax Pharmaceuticals Reports Fourth Quarter 2020 Financial Results and Provides Clinical and Business Update

WALTHAM, Mass., Dec. 18, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company has been selected for addition to...

Syndax Pharmaceuticals To Be Added to the NASDAQ Biotechnology Index

Syndax Pharmaceuticals is a clinical-stage biopharmaceutical company focused on a 2-product pipeline including SNDX-5613, a Menin inhibitor for MLLR/NPM1, and SNDX-6352, a monoclonal antibody for GVHD.

Syndax: SNDX-6352's Pivotal Trial Initiation In 2021 And $176M In Cash

WALTHAM, Mass., Dec. 9, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced today the pricing of an underwritten public...

Syndax Announces Pricing of Public Offering of Common Stock

Investors need to pay close attention to Syndax Pharmaceuticals (SNDX) stock based on the movements in the options market lately.

Implied Volatility Surging for Syndax Pharmaceuticals (SNDX) Stock Options

WALTHAM, Mass., Dec. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced updated data from the Company's Phase 1 trial of...

Syndax Pharmaceuticals Announces Additional Positive Data from Phase 1 Trial of Axatilimab in Patients with cGVHD

WALTHAM, Mass., Nov. 30, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it will host a conference call and webcast...

Syndax Pharmaceuticals to Host Axatilimab Conference Call and Webcast Featuring Two cGVHD Experts

WALTHAM, Mass., Nov. 11, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Briggs W. Morrison, M.D., Chief Executive...

Syndax Announces Presentation at Stifel 2020 Virtual Healthcare Conference

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q3 2020 Results - Earnings Call Transcript

Syndax Pharmaceuticals, Inc. (SNDX) CEO Briggs Morrison on Q2 2020 Results - Earnings Call Transcript

WALTHAM, Mass., Aug. 6, 2020 /PRNewswire/ -- Syndax Pharmaceuticals, Inc.

News for Syndax Pharmaceuticals Stock (SNDX)